谷歌诺华携手研发智能隐形眼镜技术，可矫正老花眼
|
（谷歌）很清楚，他们在某些方面天生就能力极强，富有竞争优势，但如果能找到合适的合作伙伴，建立一种共生关系，他们就能发展得更好。他们采用了竞争择优的选拔流程，利用一系列关键选择标准，最终发现谷歌和诺华是一对完美拍档。 你认为科技和制药业的这种密切融合今后会如何深刻改变医疗保健行业？ 实际上，很多一流医疗保健企业都拥有大量专有技术。如果您和诺华生物医药研究所（Novartis Institutes for Biomedical Research）所长马克•费希曼聊聊就会发现，目前流行的大数据和数据革命对诺华的大量研究来说已经起到了举足轻重的作用。 这其中的要点之一就是人们如何才能充分利用并驾驭大数据。其二就是，无论是在癌症治疗还是其他疾病治疗领域，他们能利用大数据做什么，以及大数据如何才能有助于实现个性化治疗。 这其中还有消费者的因素，即大数据能让消费者更好地控制自己的健康状况。过去人们必须去医生那儿做大量检查，而今天这些检查都可以远程无线进行。 我想，今后会有更多医疗设备企业和制药企业深入挖掘大数据，因为这能让他们从病人的视角获得更深入的认识，开发出更好的药物。（财富中文网） 译者：清远 |
[Google] recognizes that they are the natural owners for certain capabilities and certain competencies, but really it’s going to be best for them to partner and to find a symbiotic relationship that they can develop. There was a very competitive process that they ran. They had a number of key selection criteria, and ultimately the match ended up being right between Google and Novartis. How do you see the intersection of tech and pharma transforming the healthcare industry in the future? Frankly, in many top healthcare companies there’s a huge technological component. If you talk to Mark Fishman, who is the president of our Novartis Institutes for Biomedical Research, big data and the data revolution that’s happening are instrumental to a lot of our research activities within Novartis. One of the elements is how people are able to leverage and harness big data. A second element is what they can do with it then and how that enables personalization in medicine, whether it be in oncology or in other indications. There’s also this consumer piece of it, which is enabling consumers to take more control of their own healthcare. In the past you used to have to go to a doctor to do a lot of the testing that today can be done wirelessly and remotely. I think we’ll see more medical device companies and pharma companies that are interested in moving into the data realm because it gives them greater insight from a patient perspective into developing better medicines. |
